Neumora Therapeutics has reported three consecutive Phase III failures for its major depressive disorder candidate navacaprant after KOASTAL-2 and KOASTAL-3 failed to meet primary and key secondary endpoints. The company confirmed it will discontinue development of the asset and reduce
